Martin Marietta Materials, Inc.
MLMMartin Marietta Materials, Inc. is cheap for a reason. The P/E sits at the 0th percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: the P/E sits at the 0th percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn.
The price is in a downtrend (1 weeks in) while the P/E sits at the 0th percentile of its own 5-year range. Underneath, the last four quarters read deteriorating — profit −10.3% year on year, and 126% of the last 3 years' profit arrived as cash. What settles it: whether the quarters turn before the discount closes.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Martin Marietta Materials, Inc. trades at $497, in a downtrend and 1 weeks into that stage. That is −16.9% against its own 200-day average. It sits at 0% of a 52-week range of $497 to $690. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (29 weeks and counting).
Today the stock is in a downtrend — week 1 of stage 4. At $497 it trades −16.9% versus its 200-day average and sits at 0% of its 52-week range ($497–$690).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +153% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (29 weeks and counting; last ahead the week of 2026-02-27) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Martin Marietta Materials, Inc. trades at 12.2× P/E, about the cheapest it has ever traded. Its long-run median P/E is 26.2×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 12.2× is about the cheapest it has ever traded, against a long-run median of 26.2× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −42.1% against a −19.7% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +5.3%/yr price move, ~+38.1%/yr came from earnings growth and ~−32.8 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Martin Marietta Materials, Inc. reads as improving on its fundamental arc. Improving — EPS growth bottomed 4 quarters ago at −45.6% and has held its recovery at +125.7%, ROCE holding at 7.5%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.7% | −0.1% | — | — |
| Profit | −45.6% | +4.8% | — | — |
| EPS | −42.1% | +10.6% | — | — |
| Stock price | −19.7% | +5.3% | +7.7% | +11.1% |
4-Factor Sector Score
48.5/100 — rank 5 of 14 in Building Materials · 85% evidence confidence
Martin Marietta Materials, Inc. scores 48.5 out of 100 against the 14 companies it is compared with in Building Materials, ranking 5. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 14.1 + 9.4 + 16.3 + 8.7 = 48.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Martin Marietta Materials, Inc. reported $1.9 B of revenue in the Jun 26 quarter, +21.1% year on year. That is the 4th straight quarter of year-on-year growth. Over 4 years it has compounded at 3.3% a year. The last full year, FY25, came in at $6.2 B. The last four reported quarters add to $6.7 B.
FY25 revenue came in at $6.2 B (+8.7% on the year), capping 4 years at 3.3% compound. The latest quarter (Jun 26) printed $1.9 B, +21.1% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +14.9% growth against the decade's 3.3% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +14.9% over the last 4 quarters against +8.5%/yr over the last 8 — accelerating; TTM profit −1.1% vs −32.8%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Martin Marietta Materials, Inc.'s operating margin is 19.0% in the Jun 26 quarter, −6.5 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 17.9% to 43.8%. The current quarter sits inside that band.
The latest quarter's operating margin is 19.0%, −6.5 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 17.9%–43.8%.
🚨 Why the margin moved: operating margin went −6.5 pp year on year while gross margin went −6.0 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Martin Marietta Materials, Inc. earned $0.3 B of net profit in the Jun 26 quarter, −10.3% year on year. Full-year FY25 profit was $1.0 B. The 4-year compound rate is 9.1%. That is 13.3% of the quarter's revenue. The same quarter a year earlier earned $0.3 B.
Jun 26 profit was $0.3 B, −10.3% year on year. On the full year, FY25 printed $1.0 B (−45.6%), and the 4-year compound rate is 9.1%.
🚨 Why profit moved: revenue contributed +21.1% and the margin −6.5 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −4.6% vs revenue +14.9%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 126% of Martin Marietta Materials, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $1.8 B of operating cash against $1.0 B of profit. After $0.8 B of capital spending, $1.0 B was left as free cash.
FY25: operating cash of $1.8 B against reported profit of $1.0 B, leaving free cash of $1.0 B after $0.8 B of capital spending. Across the last 3 fiscal years the conversion rate is 126% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Martin Marietta Materials, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $2.0 B over the last 3 years. Averaged over those years that is 10.8% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $2.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Martin Marietta Materials, Inc. earns a ROE of 10% in FY25. Return on invested capital clears the cost of that capital by −2.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 16.1% net margin on 0.33× asset turns.
FY25 ROE is 10%.
🚨 Why the return is what it is — the wiring (FY25): 16.1% net margin × 0.33× asset turns × 1.87× balance-sheet leverage ≈ 9.9% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 6.7% − 9.2% = a −2.5 pp spread. The 9.2% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Martin Marietta Materials, Inc. paid $3.32 per share over the last four reported quarters. The most recent declaration was $0.83 for Jun 26. Against the current price of $497 that is a trailing yield of 0.67%, measured on dividends already paid rather than on a forecast.
Martin Marietta Materials, Inc. paid $3.32 per share across the last four reported quarters, most recently $0.83 for Jun 26. Against the current price of $497 the trailing twelve months work out to 0.67% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Martin Marietta Materials, Inc. carries total debt of $6.3 B against shareholder equity of $11.6 B as of Jun 26, a debt-to-equity of 0.55. On the annual view that ratio went from 0.85 in FY21 to 0.57 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $6.3 B against shareholder equity of $11.6 B — a debt-to-equity of 0.55. On the annual view, debt-to-equity went from 0.85 (FY21) to 0.57 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
4.5% of Martin Marietta Materials, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.7 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 4.5% of the float is sold short, and at typical trading volumes it would take about 4.7 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Martin Marietta Materials, Inc.: the Z-score reads 3.36. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.36 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.36.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Cementos Pacasmayo S.A.A.CPAC | 66.1/100Thin evidence · provisional52% evidence | FADING | 23.8/35 Revenue — · PAT — · OPM change 5.9 pp 45% evidence | 14.3/25 ROCE 5.8% · OPM 25.1% 76% evidence | 11.0/20 P/E 16.3× · PEG — 15% evidence | 17.0/20 RS sector 38.2% · RS bench 16.9% · 1Y 75.4%8 of 12 weeks ahead 70% evidence |
| Exact sum: 23.8 + 14.3 + 11 + 17 = 66.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2United States Lime & Minerals, Inc.USLM | 59.3/100Thin evidence · provisional58% evidence | ASLEEP | 16.4/35 Revenue — · PAT — · OPM change -3 pp 45% evidence | 16.1/25 ROCE 6.2% · OPM 40.7% 76% evidence | 9.9/20 P/E 22.4× · PEG — 15% evidence | 16.9/20 RS sector 6.1% · RS bench -10.4% · 1Y -10.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 16.1 + 9.9 + 16.9 = 59.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3James Hardie Industries plcJHX | 57.0/100Mixed-positive evidence75% evidence | LEADER | 18.8/35 Revenue 24.7% · PAT 34.5% · OPM change -9.8 pp 83% evidence | 18.0/25 ROCE 9.7% · OPM 58.6% 76% evidence | 3.9/20 P/E 99.7× · PEG 2.9 65% evidence | 16.3/20 RS sector 29.6% · RS bench 9.9% · 1Y 39.3%12 of 12 weeks ahead 70% evidence |
| Exact sum: 18.8 + 18 + 3.9 + 16.3 = 57 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 4CRH plcCRH | 50.2/100Mixed-positive evidence85% evidence | ASLEEP | 19.4/35 Revenue 6.3% · PAT 22% · OPM change 0.3 pp 95% evidence | 11.9/25 ROCE 4.4% · OPM 19.3% 76% evidence | 13.1/20 P/E 18.9× · PEG 1.01 65% evidence | 5.8/20 RS sector -13.8% · RS bench -27.5% · 1Y -23.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 11.9 + 13.1 + 5.8 = 50.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Martin Marietta Materials, Inc.this pageMLM | 48.5/100Mixed-negative evidence85% evidence | ASLEEP | 14.1/35 Revenue 14.8% · PAT -1.2% · OPM change -6.6 pp 95% evidence | 9.4/25 ROCE 2% · OPM 19.1% 76% evidence | 16.3/20 P/E 14.2× · PEG 0.65 65% evidence | 8.7/20 RS sector -8.5% · RS bench -22.9% · 1Y -19.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 9.4 + 16.3 + 8.7 = 48.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 6Eagle Materials Inc.EXP | 47.9/100Thin evidence · provisional58% evidence | ASLEEP | 16.6/35 Revenue — · PAT — · OPM change -0.7 pp 45% evidence | 12.0/25 ROCE 4.2% · OPM 17.7% 76% evidence | 10.6/20 P/E 17.8× · PEG — 15% evidence | 8.7/20 RS sector -6.3% · RS bench -21% · 1Y -22.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 12 + 10.6 + 8.7 = 47.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Vulcan Materials CompanyVMC | 47.5/100Mixed-negative evidence85% evidence | ASLEEP | 18.3/35 Revenue 6.9% · PAT 16.7% · OPM change -1.3 pp 95% evidence | 12.0/25 ROCE 3% · OPM 21.1% 76% evidence | 8.4/20 P/E 34.8× · PEG 1.9 65% evidence | 8.8/20 RS sector -6.2% · RS bench -20.9% · 1Y -18%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 12 + 8.4 + 8.8 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8CEMEX, S.A.B. de C.V.CX | 46.8/100Thin evidence · provisional58% evidence | ASLEEP | 22.1/35 Revenue — · PAT — · OPM change 3.4 pp 45% evidence | 7.3/25 ROCE 2.9% · OPM 10.2% 76% evidence | 8.5/20 P/E 779.2× · PEG — 15% evidence | 8.9/20 RS sector -1.6% · RS bench -17.1% · 1Y 12%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 7.3 + 8.5 + 8.9 = 46.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Tecnoglass Inc.TGLS | 46.0/100Mixed-negative evidence81% evidence | ASLEEP | 10.3/35 Revenue 9.8% · PAT -14.4% · OPM change -8.7 pp 83% evidence | 12.6/25 ROCE 5.1% · OPM 18% 76% evidence | 15.4/20 P/E 13.2× · PEG 0.86 65% evidence | 7.7/20 RS sector -14.4% · RS bench -27.9% · 1Y -47.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.3 + 12.6 + 15.4 + 7.7 = 46 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 10Titan America SATTAM | 42.8/100Thin evidence · provisional58% evidence | ASLEEP | 15.2/35 Revenue — · PAT — · OPM change -0.7 pp 45% evidence | 10.7/25 ROCE 3.6% · OPM 12.5% 76% evidence | 10.1/20 P/E 19.4× · PEG — 15% evidence | 6.8/20 RS sector -5.6% · RS bench -20.5% · 1Y -8.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 10.7 + 10.1 + 6.8 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Amrize AGAMRZ | 37.7/100Mixed-negative evidence75% evidence | ASLEEP | 12.9/35 Revenue 5.1% · PAT 4.2% · OPM change -0.4 pp 95% evidence | 14.3/25 ROCE 9.4% · OPM 20.5% 76% evidence | 9.7/20 P/E 24.1× · PEG — 15% evidence | 0.8/20 RS sector -18.5% · RS bench -31.5% · 1Y -23.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 14.3 + 9.7 + 0.8 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Knife River CorporationKNF | 31.1/100Adverse evidence74% evidence | ASLEEP | 20.8/35 Revenue 9.6% · PAT -18.3% · OPM change 2.4 pp 62% evidence | 3.9/25 ROCE -2.5% · OPM -21% 76% evidence | 5.3/20 P/E 31.8× · PEG 2.79 65% evidence | 1.1/20 RS sector -18.4% · RS bench -31.4% · 1Y -26.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 3.9 + 5.3 + 1.1 = 31.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Smith-Midland CorporationSMID | 28.0/100Adverse evidence75% evidence | ASLEEP | 9.4/35 Revenue 7% · PAT 11.1% · OPM change -11.3 pp 83% evidence | 5.3/25 ROCE 2.6% · OPM 8% 76% evidence | 8.9/20 P/E 16.4× · PEG 2.16 65% evidence | 4.4/20 RS sector -15.8% · RS bench -29.1% · 1Y -36.3%0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.4 + 5.3 + 8.9 + 4.4 = 28 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Suncrete, Inc.RMIX | 47.3/100Thin evidence · provisional28% evidence | FADING | 17.1/35 Revenue — · PAT — · OPM change — 2% evidence | 10.6/25 ROCE — · OPM — 15% evidence | 9.4/20 P/E 28.3× · PEG — 15% evidence | 10.2/20 RS sector 5.2% · RS bench -10.7% · 1Y 19.8%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 10.6 + 9.4 + 10.2 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Martin Marietta Materials, Inc.'s stock price today?
Martin Marietta Materials, Inc. trades at $497, −19.7% over the past year. The company is valued at $35.0 B. The stock sits at the very bottom of its 52-week range ($497–$690), −16.9% versus its 200-day average. On the tape, the price is in a downtrend, 1 weeks in. — as of 17 September 2026.
What were Martin Marietta Materials, Inc.'s latest quarterly results?
Martin Marietta Materials, Inc. reported revenue of $1.9 B and net profit of $0.3 B for the Jun 26 quarter. Revenue rose 21.1% and profit fell 10.3% year on year. Earnings per share were $4.17. The operating margin was 19.0%, 6.5 pp lower than a year earlier. — as of 17 September 2026.
What is Martin Marietta Materials, Inc.'s revenue?
Martin Marietta Materials, Inc. reported revenue of $1.9 B in the Jun 26 quarter, +21.1% year on year. For the full FY25 fiscal year, revenue was $6.2 B (+8.7%). Over the last 4 years revenue compounded at 3.3% a year. — as of 17 September 2026.
What is Martin Marietta Materials, Inc.'s profit?
Martin Marietta Materials, Inc. earned $0.3 B of net profit in the Jun 26 quarter, −10.3% year on year. Full-year FY25 profit was $1.0 B. The operating margin ran 19.0% in the latest quarter. — as of 17 September 2026.
What is Martin Marietta Materials, Inc.'s market cap?
Martin Marietta Materials, Inc.'s market capitalisation is $35.0 B at a stock price of $497. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Martin Marietta Materials, Inc.'s P/E ratio?
Martin Marietta Materials, Inc. trades at a P/E of 12.2×, at the cheapest it has been in 5 years, against a long-run median of 26.2×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Martin Marietta Materials, Inc. pay a dividend?
Yes — Martin Marietta Materials, Inc. declared $0.83 per share for Jun 26, and $3.32 per share across the last four reported quarters. — as of 17 September 2026.
What is Martin Marietta Materials, Inc.'s dividend per share?
Martin Marietta Materials, Inc.'s most recently declared dividend is $0.83 per share for Jun 26, giving $3.32 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is Martin Marietta Materials, Inc.'s dividend yield?
Martin Marietta Materials, Inc.'s trailing dividend yield is 0.67%: $3.32 declared per share across the last four reported quarters, against a share price of $497. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is Martin Marietta Materials, Inc. overvalued?
On its own history, Martin Marietta Materials, Inc. looks cheap: its P/E of 12.2× has been cheaper only 0% of the time in 5 years (long-run median 26.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Martin Marietta Materials, Inc. growing?
Not right now — Martin Marietta Materials, Inc.'s latest numbers are shrinking: latest-quarter revenue +21.1% year on year, profit −10.3%, and the margin −6.5 pp at 19.0%. The 4-year compound rates are 3.3% (revenue) and 9.1% (profit). The earnings engine currently reads: deteriorating — as of 17 September 2026.
How is Martin Marietta Materials, Inc. performing?
Martin Marietta Materials, Inc. is in a downtrend, 1 weeks in. Its latest quarter's revenue rose 21.1% and profit fell 10.3% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 29 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Martin Marietta Materials, Inc. in?
Improving — EPS growth bottomed 4 quarters ago at −45.6% and has held its recovery at +125.7%, ROCE holding at 7.5%. The read comes from the last 12 quarters of growth (revenue growth +14.9% latest, profit growth −1.1% latest, eps growth +125.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Martin Marietta Materials, Inc. in an uptrend?
No — the price is in a downtrend (week 1 of stage 4), trading −16.9% versus its 200-day average and at the very bottom of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Martin Marietta Materials, Inc. beating the market?
Not lately — on a trailing-13-week view Martin Marietta Materials, Inc. is currently behind the S&P 500 (29 weeks and counting; last ahead the week of 2026-02-27), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +153% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will Martin Marietta Materials, Inc.'s stock price go up?
This page publishes no price forecast for Martin Marietta Materials, Inc. What it measures instead: the stock price is $497, the price is in a downtrend 1 weeks in. Its P/E of 12.2× sits at the 0th percentile of its own 5-year range. — as of 17 September 2026.
Is the market betting against Martin Marietta Materials, Inc.?
Somewhat — short interest is 4.5% of Martin Marietta Materials, Inc.'s tradable float, about 4.7 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Martin Marietta Materials, Inc. have too much debt?
It is moderate — Martin Marietta Materials, Inc.'s debt-to-equity is 0.55. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Martin Marietta Materials, Inc.'s capex?
Martin Marietta Materials, Inc. spent $2.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.8 B. — as of 17 September 2026.
What is Martin Marietta Materials, Inc.'s cash flow?
Martin Marietta Materials, Inc. generated $1.8 B of operating cash flow in FY25 and $1.0 B of free cash flow after $0.8 B of capital spending. Reported profit that year was $1.0 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Martin Marietta Materials, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 126% of Martin Marietta Materials, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $1.8 B against reported profit of $1.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Martin Marietta Materials, Inc.?
On the balance sheet, the Z-score reads 3.36 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Martin Marietta Materials, Inc. in its business cycle?
Martin Marietta Materials, Inc.'s FY25 operating margin was 23.4%, against a 5-year band of 17.9%–43.8%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 19.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Martin Marietta Materials, Inc. story?
The sharpest disagreement: the P/E sits at the 0th percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Martin Marietta Materials, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Martin Marietta Materials, Inc. is cheap for a reason. The P/E sits at the 0th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the quarters turn before the discount closes. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!